Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.

Kiflemariam S, Mignardi M, Ali MA, Bergh A, Nilsson M, Sjöblom T.

J Pathol. 2014 Oct;234(2):253-61. doi: 10.1002/path.4392.

PMID:
24931216
2.
3.

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.

Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.

Neoplasia. 2006 Oct;8(10):885-8.

4.
5.

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.

Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A, Kuefer R, Tewari AK, Demichelis F, Chee MS, Gerstein MB, Rubin MA.

Neoplasia. 2009 Aug;11(8):804-11.

6.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004.

7.

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.

J Pathol. 2007 May;212(1):91-101.

PMID:
17385188
8.

Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.

Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA.

Neoplasia. 2006 Jun;8(6):465-9.

9.

Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry.

Schelling LA, Williamson SR, Zhang S, Yao JL, Wang M, Huang J, Montironi R, Lopez-Beltran A, Emerson RE, Idrees MT, Osunkoya AO, Man YG, Maclennan GT, Baldridge LA, Compérat E, Cheng L.

Hum Pathol. 2013 Oct;44(10):2227-33. doi: 10.1016/j.humpath.2013.05.005.

PMID:
23850495
10.

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS, Scardino P, Cuzick J, Cooper CS; Transatlantic Prostate Group..

Oncogene. 2008 Jan 10;27(3):253-63.

11.

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S.

Clin Cancer Res. 2008 Aug 1;14(15):4719-25. doi: 10.1158/1078-0432.CCR-08-0531.

12.

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.

Clin Cancer Res. 2009 Jul 15;15(14):4706-11. doi: 10.1158/1078-0432.CCR-08-2927.

13.

TMPRSS2-ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry.

Gopalan A, Leversha MA, Dudas ME, Maschino AC, Chang J, Al-Ahmadie HA, Chen YB, Tickoo SK, Reuter VE, Fine SW.

Histopathology. 2013 Aug;63(2):279-86. doi: 10.1111/his.12153.

14.

TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.

Swanson TA, Krueger SA, Galoforo S, Thibodeau BJ, Martinez AA, Wilson GD, Marples B.

Prostate. 2011 Oct 1;71(14):1548-58. doi: 10.1002/pros.21371.

PMID:
21394739
15.

Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ.

Am J Surg Pathol. 2011 Jul;35(7):1014-20. doi: 10.1097/PAS.0b013e31821e8761.

16.

Studies of TMPRSS2-ERG gene fusions in diagnostic trans-rectal prostate biopsies.

Attard G, de Bono JS, Clark J, Cooper CS.

Clin Cancer Res. 2010 Feb 15;16(4):1340; author reply 1340. doi: 10.1158/1078-0432.CCR-09-2253. No abstract available.

17.

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, Klein E, Rubin MA, Zhou M.

Prostate. 2011 Apr;71(5):489-97. doi: 10.1002/pros.21265.

PMID:
20878952
18.

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.

Cancer Res. 2008 May 15;68(10):3584-90. doi: 10.1158/0008-5472.CAN-07-6154.

19.

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.

Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.

Mod Pathol. 2010 Nov;23(11):1492-8. doi: 10.1038/modpathol.2010.149.

20.

Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence.

Hagen RM, Adamo P, Karamat S, Oxley J, Aning JJ, Gillatt D, Persad R, Ladomery MR, Rhodes A.

Am J Clin Pathol. 2014 Oct;142(4):533-40. doi: 10.1309/AJCPH88QHXARISUP.

Items per page

Supplemental Content

Support Center